Report includes nearly 12,000 patients who underwent Lucid's EsoGuard ® Esophageal DNA Test on samples collected using its EsoCheck ® Esophageal Cell Collection Device
Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors
Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor
Processed 2,841 EsoGuard ® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement...
Conference Call and Webcast at 8:30 AM Eastern Time
Conference Call and Webcast at 8:30 AM Eastern Time
NEW YORK , Oct. 15, 2025 /PRNewswire/ --Â Lucid Diagnostics Inc. Â (Nasdaq: LUCD) Â ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and...
The Veris Cancer Care Platform to be deployed to enhance personalized cancer care in patients undergoing systemic cancer therapy across OSUCCC – James
Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors
Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion...